Articles related to SURGICAL ONCOLOGY
Can Immunotherapy Help Some Patients with Colorectal Cancer Avoid Surgery?
Data on patients with mismatch repair deficiency (MMRD) CRC, the majority of whom could not undergo surgery due to various health conditions unrelated to cancer, were presented at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). Instead of radiation therapy or chemotherapy, the patients received immunotherapy with checkpoint inhibitors. It should be noted that the patients were treated outside of clinical trials. The overall response rate in this patient group was 74%, with 57% of those who responded experiencing complete tumor regression. Some of the patients have been in complete remission for a year or more after their diagnoses. The data indicate that immunotherapy is an effective treatment for patients who are unable to undergo surgery for a variety of reasons, including advanced age or a variety of health issues.
Gastroenterology March 6th 2023
The Journal of Nuclear Medicine (JNM)
PSMA PET/CT–based Atlas for Prostatic Bed Recurrence after Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines
The purpose of this study was to assess the relationship between the RTOG clinical target volumes (CTVs) and PSMA PET-defined recurrence topography, as well as to analyze the patterns of prostate bed (PB) recurrence in prostate cancer patients who had PSA persistence (BCP) or biochemical recurrence (BCR) following radical prostatectomy.
Oncology, Medical February 13th 2023
Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients with Surgically Resected Pancreatic Carcinoma with Node-Negative Disease After Neoadjuvant Therapy
In this multi-institutional study, AT significantly increased progression-free and overall survival in 430 patients with node-negative (N0) disease after NAT for localized pancreatic cancer (4.1 vs 2.1 and 5.3 vs 3.5 years, respectively). Patients who received neoadjuvant radiation had their overall survival benefit scaled back, while patients with perineural invasion saw an increase.
Oncology, Medical December 5th 2022
The New England Journal of Medicine
Adjuvant Pembrolizumab after Nephrectomy in Renal Cell Carcinoma
Pembrolizumab was randomly given to 496 patients, while a placebo was given to 498. The estimated percentage of patients still alive at 24 months was 96.6% in the pembrolizumab group and 93.5% in the placebo group. Pembrolizumab therapy was associated with a significantly longer disease-free survival than placebo, and there were no fatalities brought on by the treatment.
Nephrology December 5th 2022
The New England Journal of Medicine
Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death
In this randomized trial from Poland, Norway, Sweden, and the Netherlands, the study population of approximately 85,000 individuals were randomly assigned to colonoscopy screening or usual care. The risk of colorectal cancer at 10 years was 18% lower in the screening cohort.
Family Medicine/General Practice October 26th 2022
Association of Long-term Outcomes with Stereotactic Radiosurgery vs. Whole-Brain Radiotherapy for Resected Brain Metastasis
A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial When compared to WBRT, SRS alone resulted in less cognitive deterioration among long-term survivors. The link between late cognitive deterioration and WBRT was clinically significant. A significant decrease in cognition (2 SD) was linked to a decrease in overall QOL. WBRT, on the other hand, improved intracranial tumor control. This study provides detailed information about cognitive function in this patient population over time.
Oncology, Medical October 24th 2022